The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...

NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The researchers projected that more than 42,000 deaths could be averted annually, including more than 11,000 among those with type 2 diabetes, with expanded access. (HealthDay News) — Expanding access ...